Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

News Daily News

Top Endovascular News of 2024

L.A. McKeown

December 28, 2024

News Conference News VIVA 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

L.A. McKeown

November 05, 2024

Presentation TCT 2024

TCT 427: Comparison of Clinical Outcomes Between Second Generation Zotarolimus- Versus Everolimus-Eluting Stents up to 10-Year Follow-up

Presenter: Woo Jin Ahn

October 29, 2024

Presentation TCT 2024

TCT 418: Efficacy and Safety of the Bioabsorbable Polymer Everolimus-Eluting Stent in Routine Clinical Practice: Data From the IRIS-DES Registry

Presenter: Kyeong-Won Seo

October 28, 2024

Presentation TCT 2024

TCT 26: Pharmacokinetic Profile of Everolimus Eluted From the Esprit BTK Scaffold: Data From the LIFE-BTK Pharmacokinetics Sub-Study

Presenter: Richard Pin

October 27, 2024

News Daily News

DES Best for In-Stent Restenosis, but DCBs Also Viable

Michael O'Riordan

August 13, 2024

Presentation EuroPCR 2024

Randomised comparison of Abluminus DES+ sirolimus-eluting stents versus everolimus-eluting stents in coronary artery disease patients with diabetes mellitus global: the ABILITY diabetes global study

Presenter: Alexandre Abizaid

May 14, 2024

News Daily News

FDA Approves Bioresorbable Scaffold for BTK Lesions

Michael O'Riordan

April 29, 2024

News Daily News

Five Years Post-PCI, Clopidogrel Monotherapy Holds Up in STOPDAPT-2

Michael O'Riordan

January 03, 2024

Advertisement

Top Endovascular News of 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

TCT 427: Comparison of Clinical Outcomes Between Second Generation Zotarolimus- Versus Everolimus-Eluting Stents up to 10-Year Follow-up

TCT 418: Efficacy and Safety of the Bioabsorbable Polymer Everolimus-Eluting Stent in Routine Clinical Practice: Data From the IRIS-DES Registry

TCT 26: Pharmacokinetic Profile of Everolimus Eluted From the Esprit BTK Scaffold: Data From the LIFE-BTK Pharmacokinetics Sub-Study

DES Best for In-Stent Restenosis, but DCBs Also Viable

Randomised comparison of Abluminus DES+ sirolimus-eluting stents versus everolimus-eluting stents in coronary artery disease patients with diabetes mellitus global: the ABILITY diabetes global study

FDA Approves Bioresorbable Scaffold for BTK Lesions

Five Years Post-PCI, Clopidogrel Monotherapy Holds Up in STOPDAPT-2

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content